Hmmm.....I can’t agree with that. The current clinical trials are using the Gelpells (10, 50, and 100mg) an agreement for their use was constructed as part of the reverse takeover, you sell off H1 then you’ll have to fund the product to fund the IP to fund the trials. The agreement means that Phytotech can trade on the Satipharm product without great product cost, if that goes, how does MMJ support very expensive clinical trials? Furthermore, Phase III trials will take 18-24 months to complete (if the Phase II’s are successful), and then Phase IIII (if required), add in FDA approval etc. and you’re talking years. It is therefore imperative that MMJ don’t burn their bridges.....they need H1 to subsidise the cost of their trials and their “on the back burner” Israeli vaporiser. In addition, they’ll need the THC/CBD blended Gelpell to further any future clinical trials that seek a THC component.
MMJ Price at posting:
58.5¢ Sentiment: Buy Disclosure: Held
